INSM NASDAQ
Credit Risk of going bust: lower than 65% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.32 (down 99.7%), Insmed Incorporated would be worth roughly what it owes.
Total debt $579.9M against a stock market value of $20.38B.
Distance to default 6.88 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $271.8M (short-term plus half of long-term), stock volatility 61.7%; Altman Z'' -7.22. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Bridgewater, NJ 08807
US
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Koppikar Utpal | A-Award | 6,139 | — | 2026-10-19 |
| Hudson Paul | A-Award | 6,139 | — | 2026-10-19 |
| Koppikar Utpal | 0 | — | 2026-10-19 | |
| Hudson Paul | 0 | — | 2026-10-19 | |
| Brennan David R | S-Sale | 25,000 | $124.00 | 2026-09-09 |